San Francisco, 20
November 2018: The global prostate cancer therapeutics market is expected to reach USD 12.0
billion by 2025, according to a new report by Grand View Research, Inc. According
to the American Cancer Society, approximately 1 in 7 men will be diagnosed with
prostate cancer in their lifetime. As per Cancer Research, a government
institute, in the UK, 46,690 new cases of prostate cancer were diagnosed out of
which 11,287 patients died in 2014.
Supportive initiatives undertaken by key
players in collaboration with various governments to create more awareness of
clinical symptoms about prostate cancer and availability of screening &
diagnostic tests such as Prostate-Specific Antigen (PSA) and Digital Rectal
Exam (DRE) resulting in early detection. Early detection helps in quick and on
time treatment and assists in deciding treatment regimens. In addition, major
players including Astella, Inc., Sanofi, Dendreon Corporation, AstraZeneca, and
Johnson & Johnson are focusing on development of effective and safe
therapeutic products to treat tumor. Moreover, these players have various
established brands such as Zytiga, Xtandi, Eligard, Taxotere, Provenge, and
Xofigo, which hold a strong position in the market. In addition, there are many
drugs in pipeline such as Tc-99m (Progenics), radium-223 dichloride (Xofigo,
Bayer), and ODM-201 (Orion and Bayer), which are in their phase 3 studies and
are expected to enter the market during the forecast period. In addition,
patents of many existing products are expiring during the forecast period. As a
result, generic products are anticipated to penetrate the market. All these
factors together are expected to propel growth.
In Canada, Prostate Cancer Foundation of
Canada supports research, cure, and prevention of prostate cancer through an
online portal. This portal provides detailed information regarding symptoms,
diagnosis, and commercially available treatment options. Such portals offer
free access to people all around the world, which is resulting in growth.
Access
Research Report of Prostate Cancer
Therapeutics Market @ www.grandviewresearch.com/industry-analysis/prostate-cancer-therapeutics-market
Further key findings from the study suggest:
· The growing incidence of prostate cancer
across the globe is expected to drive growth
· The market is segmented into hormonal
therapy including Luteinizing Hormone Releasing Hormone (LHRH) agonist, LHRH
antagonist & antiandrogen; chemotherapy; immunotherapy, and targeted
therapy
· Zytiga (Johnson & Johnson) is
considered as a gold standard product for the treatment of prostate cancer and
holds a strong position. However, Xtandi (Astella, Inc.) and Zytiga are
competing with each other. The degree of competition is projected to elevate
during the forecast period. Thus, hormonal therapy holds the largest share.
· Provenge (Dendreon Corporation) is the only
immunotherapy drug mainly used in the treatment of advanced or metastasis of
such cancerous cells
· In addition, there are many promising
immunotherapy drugs in the pipeline such as INO-5150 SynCon and PROSTVAC
(Bavarian Nordic), which are expected to enter the market in the near future.
Thus, this drug class is projected to be the fastest growing segment.
· North America dominated the global market.
Rising prevalence and mortality rate associated with such tumors in the U.S. is
the primary reason for the dominance of the region.
· Asia Pacific is anticipated to be the
fastest growing region over the forecast period. Rising awareness regarding
prostate cancer in Asian countries including China, Japan, & India, would
be the major factor driving the growth.
· Some of the major players include, but are
not limited to, Johnson & Johnson; Astella, Inc.; Sanofi; Ipsen; Bayer AG;
AstraZeneca; Valeant Pharmaceuticals North America LLC (Dendreon Corporation).
These major players dominate the market owing to their strong brand identity
and extensive geographic reach.
Browse more reports of this category by Grand View
Research at: www.grandviewresearch.com/industry/pharmaceuticals
Grand View Research has segmented the
prostate cancer therapeutics market by drug and region:
Drugs Outlook (Revenue, USD billion; 2014 -
2025)
·
Hormonal Therapy
o
Luteinizing Hormone-Releasing Hormone
(LHRH) Antagonists
o
Luteinizing Hormone-Releasing Hormone
(LHRH) Agonists
o
Anti-Androgen
o
Chemotherapy
o
Immunotherapy
o
Targeted Therapy
Regional Outlook (Revenue, USD billion; 2014 - 2025)
·
North America
·
Europe
·
Asia Pacific
·
Latin America
·
MEA
Access Press Release of
Prostate Cancer Therapeutics Market@ www.grandviewresearch.com/press-release/global-prostate-cancer-therapeutics-market
About
Grand View Research
Grand
View Research, Inc. is a U.S. based market research and consulting company,
registered in the State of California and headquartered in San Francisco.
The company provides syndicated research reports, customized research reports, and consulting services. To help
clients make informed business decisions,
we offer market intelligence studies ensuring relevant and fact-based research
across a range of industries, from technology to chemicals, materials and
healthcare.
No comments:
Post a Comment